Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High – Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $3.42 and last traded at $3.37, with a volume of 932558 shares trading hands. The stock had previously closed at $3.34.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Stock Performance

The firm has a market capitalization of $517.03 million, a P/E ratio of -8.07 and a beta of 2.70. The firm’s 50-day moving average is $2.96 and its 200 day moving average is $2.49.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The firm had revenue of $48.07 million for the quarter, compared to analyst estimates of $46.80 million. During the same period in the previous year, the business earned ($0.14) EPS. As a group, research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XERS. Vanguard Group Inc. increased its stake in Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock valued at $16,810,000 after buying an additional 519,897 shares during the last quarter. Alpine Global Management LLC increased its stake in Xeris Biopharma by 11.1% in the 1st quarter. Alpine Global Management LLC now owns 300,000 shares of the company’s stock valued at $663,000 after buying an additional 30,000 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Xeris Biopharma by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock valued at $278,000 after buying an additional 10,632 shares during the last quarter. NEA Management Company LLC acquired a new stake in Xeris Biopharma in the 1st quarter valued at $926,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Xeris Biopharma during the 1st quarter worth about $37,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.